Proton Collaborative Group

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Proton Collaborative Group sits in the top decile of US sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count).

10 total trials 6 currently recruiting early-phase tilt top decile by trial count

Proton Collaborative Group: 10 sponsored US clinical trials, 6 recruiting.

Proton Collaborative Group sponsors 10 registered US clinical trials on ClinicalTrials.gov, 6 of them currently recruiting. 3 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 3 trials.

Top-decile sponsor footprint

Proton Collaborative Group ranks in the top decile of sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

10 total, page 1 of 1

RECRUITING Phase 3

Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy

NCT05856773
RECRUITING Phase 2

Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas

NCT02598349
RECRUITING Phase 2

Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer

NCT01766297
RECRUITING Phase 3

Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer

NCT01492972
RECRUITING NA

Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy

NCT00969111
RECRUITING

Registry Study for Radiation Therapy Outcomes

NCT01255748
ACTIVE NOT RECRUITING Phase 1

A Phase I/II Study of Hypofractionated Proton Therapy for Stage II-III Non-Small Cell Lung Cancer

NCT01770418
ACTIVE NOT RECRUITING Phase 2

Proton Radiation for Stage II/III Breast Cancer

NCT01758445
ACTIVE NOT RECRUITING Phase 3

Study of Hypo-fractionated Proton Radiation for Low Risk Prostate Cancer

NCT01230866
TERMINATED Phase 2

External Beam Radiation With or Without Chemotherapy to Treat High Risk Prostate Cancer

NCT01603420

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 4
Phase 3 3

Therapeutic Areas

Breast Cancer 3
Prostate Cancer 3
Breast Tumor 2
Cancer of the Breast 2
Breast Neoplasm 2
Neoplasms 1
Lung Neoplasms 1
Pancreatic Cancer 1

What is open in the Proton Collaborative Group pipeline

6 recruiting of 10 indexed (60% open).

Phase mix: 3 late (III/IV) vs 5 early (I/II) (early-phase heavy).

Top condition: Breast Cancer (3 trials), 7 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Proton Collaborative Group: open-pipeline peers nationwide

Peers matched on 10 registered trials and 60% open enrollment, not the therapeutic-area sidebar.

Proton Collaborative Group sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 4681012 0%20%40%60%80% Total trials Recruiting share Proton Collaborative GroupAdamas PharmaceuticalsAdverum BiotechnologiesAevi Genomic Medicine, LLC, a Cerecor companyAgouron PharmaceuticalsAlaska Native Tribal Health ConsortiumAnwaar SaeedAutolus LimitedBeam Therapeutics
Proton Collaborative Group sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Proton Collaborative Group sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 10 trials (± recruiting share)

Sponsors near 60% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Proton Collaborative Group page

10 registered trials is a research-attention snapshot, not an endorsement of Proton Collaborative Group or any single study.

  • 6 of Proton Collaborative Group's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Breast Cancer is the condition Proton Collaborative Group studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Proton Collaborative Group pipeline card: 10 registered trials from official public datasets.Report a data error.